Corline Biomedical AB OMXSTO:CLBIO:
SIGNS 10-YEAR AGREEMENT WITH KARDIUM
Corline Biomedical Signs 10-Year Agreement With Kardium
Earlier from Corline Biomedical Ab
- CLBIO: Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales
- CLBIO: Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism
- CLBIO: 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®
- CLBIO: Sharply reduced costs and strategic focus position Corline for growth and profitability by 2025